Literature DB >> 8466250

Recommendations on the dietary management of phenylketonuria. Report of Medical Research Council Working Party on Phenylketonuria.

.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8466250      PMCID： PMC1793880          DOI： 10.1136/adc.68.3.426

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN： 0003-9888            Impact factor:   3.791


× No keyword cloud information.
  74 in total

1.  Measurement of neurotransmitter metabolites in the cerebrospinal fluid of phenylketonuric patients under dietary treatment.

Authors:  A B Burlina; L Bonafé; V Ferrari; A Suppiej; F Zacchello; A P Burlina
Journal:  J Inherit Metab Dis       Date:  2000-06       Impact factor: 4.982

2.  Maternal phenylketonuria: low phenylalaninemia might increase the risk of intra uterine growth retardation.

Authors:  Raphaël Teissier; Emmanuel Nowak; Murielle Assoun; Karine Mention; Aline Cano; Alain Fouilhoux; François Feillet; Hélène Ogier; Emmanuel Oger; Loïc de Parscau
Journal:  J Inherit Metab Dis       Date:  2012-06-05       Impact factor: 4.982

Review 3.  Phenylketonuria: old disease, new approach to treatment.

Authors:  H L Levy
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-02       Impact factor: 11.205

4.  Living with phenylketonuria: perspectives of patients and their families.

Authors:  C Bilginsoy; N Waitzman; C O Leonard; S L Ernst
Journal:  J Inherit Metab Dis       Date:  2005       Impact factor: 4.982

5.  A new protein substitute for adolescents and adults with maple syrup urine disease (MSUD).

Authors:  P Hallam; M Lilburn; P J Lee
Journal:  J Inherit Metab Dis       Date:  2005       Impact factor: 4.982

6.  Executive function in treated phenylketonuria as measured by the one-back and two-back versions of the continuous performance test.

Authors:  P Griffiths; R Campbell; P Robinson
Journal:  J Inherit Metab Dis       Date:  1998-04       Impact factor: 4.982

7.  Treatment products and approaches for phenylketonuria: improved palatability and flexibility demonstrate safety, efficacy and acceptance in US clinical trials.

Authors:  A P Prince; M P McMurray; N R Buist
Journal:  J Inherit Metab Dis       Date:  1997-08       Impact factor: 4.982

Review 8.  Lipid status and fatty acid metabolism in phenylketonuria.

Authors:  M Giovannini; G Biasucci; C Agostoni; D Luotti; E Riva
Journal:  J Inherit Metab Dis       Date:  1995       Impact factor: 4.982

Review 9.  What we know that could influence future treatment of phenylketonuria.

Authors:  C N Sarkissian; A Gámez; C R Scriver
Journal:  J Inherit Metab Dis       Date:  2008-08-03       Impact factor: 4.982

10.  Intelligence in mild atypical phenylketonuria.

Authors:  P M Costello; M G Beasley; S L Tillotson; I Smith
Journal:  Eur J Pediatr       Date:  1994-04       Impact factor: 3.183
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.